Predictors of Left Ventricular Ejection Fraction Decrease in Patients With ST-Segment Elevation Myocardial Infarction

Aim. To identify predictors and construct a model for predicting left ventricular (LV) ejection fraction (EF) in patients with ST-segment elevation myocardial infarction (STEMI).
Material and methods. This was a prospective registry study of patients with STEMI admitted within the first 24 hours of the disease onset. Patients were evaluated and treated according to the current clinical guidelines. On the first day of STEMI, concentrations of growth stimulating factor, proprotein convertase subtilisin-kexin type 9 (PCSK9), N-terminal pro-B-type natriuretic peptide (NT-proBNP), and high-sensitivity troponin I and C-reactive protein were measured. Echocardiography was performed on the first day and on day 10-12 of admission; LVEF was calculated by the Simpson method. The study included 138 patients; 3 patients were excluded from this part of the study due to death before repeat echocardiography. Based on the LVEF value on day 10-12 of STEMI, the patients were divided into the groups with preserved LVEF (pLVEF) ≥50% (n=34), reduced LVEF (rLVEF) ≤40% (n=21), and moderately reduced LVEF (mrLVEF) 41-49% (n=80).
Results. The ordinal regression analysis showed that the factors influencing LVEF in STEMI patients included a history of chronic heart failure, Killip class II–IV acute heart failure at the index hospitalization, the development of LV dilation and postinfarction aneurysm, and an increase in NTproBNP. Based on the obtained estimates of the regression parameters, a prognostic model was constructed that showed the highest sensitivity of the model for predicting rLVEF, 94.4%, mrLVEF, 92.9%, and a lower sensitivity for predicting pLVEF, 62.5%.
Conclusion. In the presence of a history of chronic heart failure, Killip class II–IV acute heart failure, developed LV dilation and postinfarction aneurism, and elevated NTproBNP, patients with STEMI are expected to have lower LVEF values.

1. Parshikova E.N., Filippov E.V. Mortality from all causes in patients with myocardial infarction with elevation of st segment depending on the type of reperfusion therapy (data of Ryazan region, 2018-2020). I.P. Pavlov Russian Medical Biological Herald. 2020;28(4):479–87. DOI: 10.23888/PAVLOVJ2020284479-487

2. Yakushin S.S., Filippov E.V. Analysis of mortality rate from diseases of circulatory system and cardiovascular diseases in the Ryazan region in the period 2012-2016. Eruditio Juvenium. 2018;6(3):448–61. DOI: 10.23888/HMJ201863448-461

3. Choi Y, Lee KY, Kim SH, Kim KA, Hwang B-H, Choo EH et al. Predictors for early cardiac death after discharge from successfully treated acute myocardial infarction. Frontiers in Medicine. 2023;10:1165400. DOI: 10.3389/fmed.2023.1165400

4. Desta L, Jernberg T, Löfman I, Hofman-Bang C, Hagerman I, Spaak J et al. Incidence, Temporal Trends, and Prognostic Impact of Heart Failure Complicating Acute Myocardial Infarction. The SWEDEHEART Registry (Swedish Web‐System for Enhancement and Development of Evidence‐Based Care in Heart Disease Evaluated According to Recommended Therapies): a study of 199,851 patients admitted with index acute myocardial infarctions, 1996 to 2008. JACC: Heart Failure. 2015;3(3):234–42. DOI: 10.1016/j.jchf.2014.10.007

5. Taniguchi T, Shiomi H, Morimoto T, Watanabe H, Ono K, Shizuta S et al. Incidence and Prognostic Impact of Heart Failure Hospitalization During Follow-Up After Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction. The American Journal of Cardiology. 2017;119(11):1729–39. DOI: 10.1016/j.amjcard.2017.03.013

6. Averkov O.V., Duplyakov D.V., Gilyarov M.Yu., Novikova N.A., Shakhnovich R.M., Yakovlev A.N. et al. 2020 Clinical practice guidelines for Acute ST-segment elevation myocardial infarction. Russian Journal of Cardiology. 2020;25(11):251–310. DOI: 10.15829/29/1560-4071-2020-4103

7. Otto С.М. Clinical echocardiography: a practical guide. -M.: Logosfera;2019. - 1352 p. ISBN 978-5-98657-064-8

8. Wohlfahrt P, Jenča D, Melenovský V, Šramko M, Kotrč M, Želízko M et al. Trajectories and determinants of left ventricular ejection fraction after the first myocardial infarction in the current era of primary coronary interventions. Frontiers in Cardiovascular Medicine. 2022;9:1051995. DOI: 10.3389/fcvm.2022.1051995

9. Lenselink C, Ricken KWLM, Groot HE, De Bruijne TJ, Hendriks T, Van Der Harst P et al. Incidence and predictors of heart failure with reduced and preserved ejection fraction after ST‐elevation myocardial infarction in the contemporary era of early percutaneous coronary intervention. European Journal of Heart Failure. 2024;26(5):1142–9. DOI: 10.1002/ejhf.3225

10. Zhang Z, Guo J. Predictive risk factors of early onset left ventricular aneurysm formation in patients with acute ST-elevation myocardial infarction. Heart & Lung. 2020;49(1):80–5. DOI: 10.1016/j.hrtlng.2019.09.005

11. Liang J, Zhang Z. Predictors of in-hospital heart failure in patients with acute anterior wall ST-segment elevation myocardial infarction. International Journal of Cardiology. 2023;375:104–9. DOI: 10.1016/j.ijcard.2023.01.002

12. Westman PC, Lipinski MJ, Luger D, Waksman R, Bonow RO, Wu E et al. Inflammation as a Driver of Adverse Left Ventricular Remodeling After Acute Myocardial Infarction. Journal of the American College of Cardiology. 2016;67(17):2050–60. DOI: 10.1016/j.jacc.2016.01.073

13. Kologrivova I, Shtatolkina M, Suslova T, Ryabov V. Cells of the Immune System in Cardiac Remodeling: Main Players in Resolution of Inflammation and Repair After Myocardial Infarction. Frontiers in Immunology. 2021;12:664457. DOI: 10.3389/fimmu.2021.664457

14. Mazhar J, Mashicharan M, Farshid A. Predictors and outcome of noreflow post primary percutaneous coronary intervention for ST elevation myocardial infarction. IJC Heart & Vasculature. 2016;10:8–12. DOI: 10.1016/j.ijcha.2015.11.002

15. Rezkalla SH, Stankowski RV, Hanna J, Kloner RA. Management of No-Reflow Phenomenon in the Catheterization Laboratory. JACC: Cardiovascular Interventions. 2017;10(3):215–23. DOI: 10.1016/j.jcin.2016.11.059

16. Kristensen SL, Jhund PS, Køber L, Preiss D, Kjekshus J, McKelvie RS et al. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure. 2015;17(2):169–76. DOI: 10.1002/ejhf.211

17. Omland T, Persson A, Ng L, O’Brien R, Karlsson T, Herlitz J et al. NTerminal Pro-B–Type Natriuretic Peptide and Long-Term Mortality in Acute Coronary Syndromes. Circulation. 2002;106(23):2913–8. DOI: 10.1161/01.CIR.0000041661.63285.AE

18. Celebi S, Celebi OO, Cetin S, Cetin HO, Tek M, Gokaslan S et al. The Usefulness of Admission Plasma NT-pro BNP Level to Predict Left Ventricular Aneurysm Formation after Acute ST-Segment Elevation Myocardial Infarction. Arquivos Brasileiros de Cardiologia. 2022;113(6):1129–37. DOI: 10.5935/abc.20190226

19. Dyleva Yu.A., Gruzdeva O.V., Akbasheva О.E., Uchasova E.G., Fedorova N.V., Chernobay A.G. et al. Significance of stimulating growth factor ST2 and NT-proBNP in assessment of postinfarction remodeling of the heart. Russian Journal of Cardiology. 2015;20(12):63–71. DOI: 10.15829/1560-4071-2015-12-63-71

20. Bordejevic DA, Pârvănescu T, Petrescu L, Mornoș C, Olariu I, Crișan S et al. Left Ventricular Remodeling Risk Predicted by Two-Dimensional Speckle Tracking Echocardiography in Acute Myocardial Infarction Patients with Midrange or Preserved Ejection Fraction in Western Romania. Therapeutics and Clinical Risk Management. 2021;17:249–58. DOI: 10.2147/TCRM.S295251

21. Liu S, Jiang Z, Zhang Y, Pang S, Hou Y, Liu Y et al. A nomogramic model for predicting the left ventricular ejection fraction of STEMI patients after thrombolysis-transfer PCI. Frontiers in Cardiovascular Medicine. 2023;10:1178417. DOI: 10.3389/fcvm.2023.1178417

22. Von Lewinski D, Kolesnik E, Tripolt NJ, Pferschy PN, Benedikt M, Wallner M et al. Empagliflozin in acute myocardial infarction: the EMMY trial. European Heart Journal. 2022;43(41):4421–32. DOI: 10.1093/eurheartj/ehac494

23. Bellis A, Mauro C, Barbato E, Trimarco B, Morisco C. The PARADISE‐ MI trial: a new opportunity to improve the left ventricular remodelling in reperfused STEMI. ESC Heart Failure. 2022;9(6):3698– 701. DOI: 10.1002/ehf2.14159